• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Liver international : >Strong prediction of virological response to combination therapy by IL28B gene variants rs12979860 and rs8099917 in chronic hepatitis C genotype 4
【24h】

Strong prediction of virological response to combination therapy by IL28B gene variants rs12979860 and rs8099917 in chronic hepatitis C genotype 4

机译：IL28B基因变体rs12979860和rs8099917对慢性丙型肝炎基因型4的联合治疗的病毒学应答的强有力预测

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background: A strong association between single nucleotide polymorphisms (SNPs) of IL28B and treatment outcomes of pegylated interferon-α (PEG IFNα) and ribavirin (RBV) has been shown in chronic hepatitis C (CHC) patients with genotype 1. Aim: This study aimed to assess two SNPs of IL28B, rs12979860 and rs8099917, in predicting sustained virological responses (SVR) to treatment of CHC patients with genotype 4 (HCV-4). The value of rs8099917 was investigated in carriers of unfavourable genotypes of rs12979860. Methods: This study included 119 CHC patients with HCV-4 receiving combination therapy. Both SNPs of IL28B were determined by real-time detection polymerase chain reaction. Results: Genotypes CC/CT/TT of rs12979860 were found in 42 (35.3%), 56 (47.1%) and 21 (17.6%) and rs8099917 TT/TG/GG were found in 74 (62.2%), 40 (33.6%) and 5 (4.2%). In carriers of rs12979860 CC and rs8099917 TT, the rate of SVR was 87.5 and 65.7% respectively. In 54 patients heterozygous for the C allele of rs12979860, testing of rs8099917 revealed SVR in 42.3% of carriers of the TT genotype but no such responses in carriers of TG or GG (P < 0.0001, OR = 47.3, 95% CI: 2.33-767.2). By multivariate analysis, predictors of SVR were baseline ALT (P = 0.014, OR = 6.3, 95% CI: 1.45-27.33), rs12979860 CC (P = 0.001, OR = 13.48, 95% CI: 2.95-61.69) and rs8099917 TT (P = 0.027, OR = 7.5, 95% CI: 1.25-44.88). Conclusion: In CHC genotype 4 patients, favourable genotypes of both SNPs of IL28B are valuable for predicting SVR. Additional genotyping of rs8099917 in carriers of the heterozygous C allele of rs12979860 can improve the prediction of SVR.
机译：背景：在基因型为1的慢性丙型肝炎（CHC）患者中，IL28B的单核苷酸多态性（SNPs）与聚乙二醇化干扰素-α（PEGIFNα）和利巴韦林（RBV）的治疗结果之间存在密切关联。目的：本研究旨在评估IL28B的两个SNP，即rs12979860和rs8099917，以预测对基因型4（HCV-4）的CHC患者的持续病毒学应答（SVR）。在具有不利基因型rs12979860的携带者中研究了rs8099917的价值。方法：本研究纳入119位接受HCV-4联合治疗的CHC患者。 IL28B的两个SNP通过实时检测聚合酶链反应确定。结果：分别在42（35.3％），56（47.1％）和21（17.6％）中发现了rs12979860的CC / CT / TT基因型，在74（62.2％），40（33.6％）中发现了rs8099917 TT / TG / GG。 ）和5（4.2％）。在rs12979860 CC和rs8099917 TT的载体中，SVR的发生率分别为87.5和65.7％。在rs12979860的C等位基因杂合的54例患者中，对rs8099917的检测显示TT基因型携带者中42.3％的患者具有SVR，但TG或GG携带者中无此反应（P <0.0001，OR = 47.3，95％CI：2.33- 767.2）。通过多变量分析，SVR的预测因子为基线ALT（P = 0.014，OR = 6.3，95％CI：1.45-27.33），rs12979860 CC（P = 0.001，OR = 13.48，95％CI：2.95-61.69）和rs8099917 TT （P ＝ 0.027，OR ＝ 7.5，95％CI：1.25-44.88）。结论：在CHC基因型4患者中，IL28B两种SNPs的有利基因型对于预测SVR具有重要价值。 rs12979860杂合C等位基因携带者中rs8099917的其他基因分型可以改善SVR的预测。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号